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Abstract 
Hyponatraemia is the most common electrolyte disorder seen in clinical practice and the 
consequences can range from minor symptoms to life-threatening complications including 
seizures and cardiorespiratory distress. These effects occur as a result of fluid shifts due to 
deranged serum tonicity and subsequent cerebral oedema. The appropriate assessment and 
management of patients with hyponatraemia is not always achieved in clinical practice, 
which is partly related to challenges in teaching with limited clinical guidance. Recently, the 
European Society of Endocrinology, European Society of Intensive Care Medicine and 
European Renal Association–European Dialysis and Transplant Association produced clinical 
practice guidelines to focus on appropriate investigation and management of these patients.  
 
Within this manuscript, we highlight the key points from these guidelines which are most 
pertinent to doctors of all specialities to improve the care of patients with this common 
electrolyte disorder. 
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Background 
Hyponatraemia is the commonest electrolyte disorder seen in hospital inpatients in the UK. 
Approximately 15% of inpatients have a serum sodium concentration <135mmol/L, 4% 
<130mmol/L and 2% <125mmol/L [1]. This prevalence is greater in the acute critical setting 
such as intensive care, where approximately 30% of patients have a serum sodium 
<134mmol/L [2]. Clinical presentation and subsequent management is dependent on the 
nature and severity of the clinical symptoms and signs, and the aetiology of the 
hyponatraemia. Patients with acute, severe symptoms will require specialist input for rapid 
correction of the serum sodium. Such patients are also at a higher risk of morbidity, length of 
hospital stay and mortality [1, 3]. Patients with hyponatraemia are seven times more likely to 
die than those without hyponatraemia in hospital [4]. Hospital doctors regularly manage 
patients with hyponatraemia across a range of inpatient wards, and therefore the management 
of this common electrolyte disorder is important in routine clinical practice. However optimal 
management of these patients is not always achieved, which is in part due to a lack of 
knowledge. Within this manuscript, we summarise the key points from the joint guidelines 
from the European Society of Endocrinology, European Society of Intensive Care Medicine 
and European Renal Association–European Dialysis and Transplant Association [5].  
 
Hyponatraemia is defined as serum sodium <135mmol/L. It may be classified temporally 
(acute <48 hours; chronic >48 hours) or by the absolute serum sodium level [5]. Mild (130-
135mmol/L), moderate (125-130mmol/L) or severe (<125mmol/L) hyponatraemia presents 
with non-specific signs and symptoms, and are summarised in Table 1. However, patients 
should be assessed and treated on the basis of their symptoms rather than the absolute serum 
sodium level or time frame in which hyponatraemia develops. 
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Clinical features  
The clinical presentation of hyponatraemia is often non-specific but may include life-
threatening seizures and cardiorespiratory arrest. Patients with mild to moderate 
hyponatraemia may have symptoms such as nausea, confusion and headache, whereas those 
with moderate to severe hyponatraemia will present with vomiting, cardiorespiratory distress, 
seizures and reduced consciousness [3, 5], as summarised in Table 1. A patient is likely to 
present with more severe symptoms if they have acute-onset hyponatraemia as cerebral 
oedema develops secondary to the reduced serum osmolality. In chronic hyponatraemia there 
is lower risk of neurological dysfunction as the brain initiates counter-regulatory mechanisms 
to reduce cerebral oedema, typically over a 24-48 hour period [3]. This explains the rationale 
for classifying acute hyponatraemia as that which occurs within 48 hours and the relative 
severity of the symptoms that patients’ develop [5]. Importantly, there must be a normal 
serum sodium concentration demonstrated in the previous 48 hours for acute hyponatraemia 
to be diagnosed, otherwise the assumption must be that the patient has a chronic 
hyponatraemia. 
Table 1 
 
Subtle symptoms  Mild symptoms  Severe symptoms 
• Gait abnormalities 
• Falls 
• Reduced 
concentration 
• Cognitive deficits 
• Increased 
osteoporosis and 
fractures. 
• Nausea 
• Confusion 
• Headache 
• Vomiting 
• Cardiorespiratory   
distress 
• Abnormal and deep sleep 
• Seizures 
• Coma 
 
Table 1:  Summary of clinical features associated with hyponatraemia. 
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The aetiology and assessment of hyponatraemia 
A detailed clinical assessment of patients with mild to moderate hyponatraemia is essential, 
as aetiology will guide clinical management. Patients with severe or life-threatening 
hyponatraemia may require rapid correction of their serum sodium (see below), and therefore 
specialist input may be required prior to obtaining a clinical assessment.  
 
Hyponatraemia in the presence of high serum osmolality may occur as a consequence of 
hyperglycaemia, termed hypertonic hyponatraemia. Hyperglycaemia may result in a fluid 
shift by osmosis from the intracellular to the extracellular fluid compartment, thus diluting 
serum sodium levels [6]. When hyperglycaemia is corrected, the sodium concentration will 
correct as fluid returns by osmosis to the intracellular compartment. Therefore, when treating 
patients with hyperglycaemia it is important to control the rate at which plasma glucose is 
lowered, to minimise the associated risk of cerebral oedema that can occur [7]. 
 
Once non-hypotonic hyponatraemia has been excluded, it is important to measure the serum 
osmolality and both the urine osmolality and sodium concentration. In the instance the serum 
osmolality is >275mOsmol/Kg then isotonic or hypertonic hyponatraemia is present. 
Conversely, if the serum osmolality is <275mOsmol/Kg, the patient has a hypotonic 
hyponatraemia. The urine osmolality and urinary sodium can help identify the aetiology. In 
most instances when the urine osmolality <100mOsmol/Kg, it is likely that the patient has 
excess water intake. Commonly, when the urine osmolality >100mOsmol/Kg and urinary 
sodium is <30mmol/L there is a low effective arterial volume (see below). In those patients 
with a urine osmolality >100mOsmol/kg and a urinary sodium >30mmol/L assessment of the 
patients extracellular fluid (ECF) status should be undertaken (see section below). If the ECF 
volume is low, the patient’s hyponatraemia may be secondary to diuretic use, primary adrenal 
6	  
	  
insufficiency, vomiting and cerebral or renal salt wasting. For patients who are clinically 
euvolemic, consider the syndrome of inappropriate diuresis (SIAD), secondary adrenal 
insufficiency, hypothyroidism as well as drug-induced aetiologies. This is shown in Figure 1. 
 
Assessing extracellular fluid status 
The assessment of ECF status is often difficult, and is most useful in patients with 
hyponatraemia when urine osmolality and urinary sodium levels can also be reviewed. The 
aetiological basis of hyponatraemia can be classified by the fluid status of the patient as 
hypovolemic, euvolemic or hypervolemic hyponatraemia. Major causes of hypovolemic 
hyponatraemia include diuretics, renal failure, and adrenal insufficiency; causes of euvolemic 
hyponatraemia include SIAD and hypothyroidism; hypervolemic hyponatraemia is caused by 
chronic medical conditions such as cardiac failure, hepatic disease, and renal disease [8]. 
Table 2 summarises the causes of hyponatraemia by fluid status. 
Table 2 
Hypovolaemia Euvolaemia Hypervolaemia 
• GI loss (vomiting, diarrhoea) 
• Diuretics (thiazides) 
• Primary adrenal 
insufficiency 
• Cerebral salt wasting  
• Renal disease  
   (salt-losing nephropathies) 
•  ‘Third spacing’ 
(pancreatitis, sepsis,       
    bowel obstruction) 
• SIAD 
• Secondary adrenal 
insufficiency 
• Hypothyroidism 
• High water/low solute 
intake (primary 
polydipsia) 
• Renal failure 
• Heart failure 
• Liver failure 
• Nephrotic 
syndrome 
Table 2:  Classification of hyponatraemia based on Extracellular Fluid volume (ECF). 
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The clinical history will guide the assessment as the patient may have had diarrhoea, 
vomiting, polyuria or a pre-existing medical condition such as cardiac or renal failure. At this 
point in the assessment, ask about symptoms of hyponatraemia as this may change the 
approach to management (Figure 2). Signs of hypovolemia include dry mucous membranes, 
tachycardia and hypotension. Hypervolemic patients present with raised jugular venous 
pressure, peripheral and pulmonary oedema [9]. Euvolemia is determined primarily through 
the absence of other signs. However, clinical examination alone to assess a patient’s fluid 
status is often difficult, especially when assessing elderly patients who may demonstrate 
inconsistent signs [10]. Therefore, consideration of body weight, fluid balance charts and 
intravenous fluid prescription is also essential.  
In many cases of hyponatraemia there is an increased secretion of antidiuretic hormone 
(ADH) which can further reduce the serum sodium level, termed SIAD. In those with 
hypovolemic hyponatraemia, ADH is released from the posterior pituitary gland via a 
baroceptor-mediated reflex, which increases renal water reabsorption. This will help to 
restore intravascular volume, but at the cost of reducing serum sodium levels and the serum 
osmolality further. In hypervolemic patients with hyponatraemia there is often a concurrent 
diagnosis of cardiac failure or hepatic impairment, resulting in reduced cardiac output and 
peripheral vasodilation respectively. This causes a similar reflex as described above and 
further water reabsorption resulting in both fluid overload and a chronic hyponatraemia [11].  
In practice, it is difficult to know the prevalence of the different causes of hyponatraemia 
because often a full clinical assessment has not been completed and the causes differ between 
specialities and patient subgroups. Commoner causes include medication-induced 
hyponatraemia [8] and SIAD. A recent study in a sample of elderly patients admitted with 
fragility fractures, observed that hyponatraemia in >75% was potentially related to the use of 
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thiazide diuretics [12]. Other medications which may result in hyponatraemia include 
antipsychotics, antiepileptic medications, selective serotonin reuptake inhibitors (SSRIs), 
angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARBs), 
and proton-pump inhibitors (PPIs). SIAD is described in further detail below.  
 
Therefore patients with hyponatraemia should have serum urea and electrolytes, glucose, 
osmolality, and thyroid function tests measured in addition to urine analysis for osmolality 
and sodium concentrations. In patients with suspected adrenal insufficiency, one should also 
consider testing a 9am serum cortisol level or performing a short synacthen test. 
 
Syndrome of inappropriate diuresis 
This syndrome results from the excessive, unregulated secretion of ADH which results in the 
kidney’s inability to effectively dilute urine. Reduced serum osmolality and hyponatraemia 
result from the excess water reabsorption in the renal tubules. SIAD is the commonest cause 
of euvolemic hyponatraemia [13], but should be considered as a diagnosis of exclusion after 
other causes of hyponatraemia have been excluded [5]. Beware that the other conditions 
discussed previously may result in the appropriate increased secretion of ADH and may 
therefore present with a similar clinical picture [14].  
 
The diagnosis of SIAD requires the exclusion of the other causes of hyponatraemia which 
result in the physiological secretion of ADH. The biochemical markers suggestive of 
increased ADH secretion include a serum osmolality <275mOsmol/kg with urine osmolality 
>100mOsmol/kg. The urine osmolality is inappropriately concentrated relative to the plasma 
osmolality, and the urinary sodium concentration is typically >30mmol/L. The patient should 
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be clinically euvolemic and have normal adrenal, thyroid and pituitary function. These 
patients should also have normal renal function and no recent history of diuretic use [13, 15]. 
There are many causes of SIAD, which are also summarised in Table 3. These include 
malignancies of the lung, gastrointestinal (GI) and genitourinary (GU) tracts; pneumonia; 
neurological disorders such meningitis/encephalitis, subdural haematomas and stroke. 
Medications such as antidepressants, antipsychotics and antiepileptic medications are also 
known to cause SIAD [16]. However, in practice there is often no attributable cause. 
 
Table 3 
Malignant 
Disorders 
Pulmonary 
Disorders 
CNS Disorders Medications 
Carcinoma 
• Lung 
• Oropharynx 
• GI Tract 
• GU Tract 
• Lymphoma 
• Sarcoma 
Infections 
• Bacterial or Viral 
Pneumonia 
• TB 
• Asthma 
• Cystic Fibrosis 
Infection 
• Meningitis 
• Encephalitis 
 
Vascular 
• Subdural 
• Subarachnoid 
haemorrhage 
• Stroke 
Antidepressants 
• SSRIs and SNRIs 
 
Anticonvulsants 
• Carbamazepine 
• Sodium Valproate 
• Lamotrigine 
 
Antipsychotics 
• Phenothiazide’s 
• Butyrophenones 
 
Table 3:  Summary of the aetiology of SIAD 
 
Cerebral/Renal salt wasting syndrome 
Cerebral/renal salt wasting syndrome is a rare condition which leads to a mild-to-moderate 
hyponatraemia, and is commonly associated with intracranial bleeds (subarachnoid 
haemorrhage, subdural haematomas), cerebral injury or brain tumours. The term cerebral salt 
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wasting syndrome is commonly used due to its significant association with the cerebral 
pathologies listed. However, the syndrome often occurs without cerebral pathology, and as 
such the term renal salt-wasting syndrome is often considered to be more appropriate [17]. 
The mechanism of the syndrome is thought to be initiated by the release of a natriuretic factor 
which results in the increased renal excretion of sodium and subsequent volume depletion. As 
a result of the subsequent intravascular volume depletion, there is release of ADH and 
increased renin-angiotensin-aldosterone activity to reduce the rate of diuresis [18]. Crucially, 
it must be recognised that the release of ADH in this setting is an appropriate response to the 
volume depletion, and this often makes it clinically difficult to differentiate cerebral/renal salt 
wasting syndrome from SIAD. 
 
Investigation of these patients will demonstrate similar laboratory findings as observed in 
patients with SIAD, with low serum osmolality (<275mOsmol/kg), high urine osmolality 
(>100mOsmol/kg) and high urinary sodium concentration (>30mmol/L). However, on 
examination patients with cerebral salt wasting are dehydrated, and as described above, 
patients with SIAD are euvolemic. Treatment of cerebral salt wasting syndrome is usually 
best achieved with intravenous supplementation of 0.9% sodium chloride, and specialist use 
of fludrocortisone [19]. In most patients there is spontaneous resolution within 2 weeks, 
though in elderly patients prolonged treatment may be required. 
 
Approaches to management 
The clinical management of patients with acute hyponatraemia take account of the patient’s 
symptoms, the duration of onset (i.e. acute or chronic), fluid balance and absolute sodium 
level. The available guidelines consider the management of patients with severe and 
moderately severe symptoms separately as summarised in Figure 2 [5]. 
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Management of patients with severe symptoms 
The management of patients with hyponatraemia with severe symptoms is best achieved by 
senior and specialist doctors working in a closely monitored environment in which there is 
easily available blood monitoring, and as such doctors who are uncertain of appropriate 
management strategies should seek help from appropriate medical or critical care teams as 
early as possible. Treatment is initiated with an intravenous infusion of 150mls 3% 
hypertonic sodium chloride over 20 minutes. Following the infusion the serum sodium is 
measured and a further 150ml infusion can be administered whilst waiting for the result. If 
the patient’s symptoms have not adequately improved, continue with the intravenous 
hypertonic saline infusions, regularly checking the serum sodium at least every 4 hours. The 
hypertonic saline infusions should be stopped when the patient’s symptoms improve, the 
serum sodium concentration increases by 10mmol/L or the serum sodium is 130mmol/L. In 
patients who respond to treatment, consider a slow infusion of 0.9% sodium chloride and 
cause-specific treatment. In these patients, the serum sodium should be checked after 6 hours, 
and subsequently at 12 hours, and daily thereafter. If the patient requires concurrent fluid 
resuscitation, this overrides the risk of rapid correction of hyponatraemia (section below). 
 
Management of patient’s without severe symptoms 
The clinical management of hyponatraemia without severe symptoms is guided by the rate of 
onset. If the onset is acute, consider stopping any contributing fluids and medications. If the 
drop in serum sodium is >10mmol/L consider giving 150mls 3% sodium chloride over 20 
minutes intravenously and measure the serum sodium after 4 hours. Following this, undertake 
the investigations as described above and initiate cause-specific treatment. It should be noted 
that this approach in management should be undertaken only with specialist supervision and 
facilities to regularly check serum sodium levels. 
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In patients with chronic hyponatraemia without severe symptoms management should consist 
of stopping any contributing non-essential medications or fluids. Further treatment takes 
account of the fluid status. Patients with hypervolemia or SIAD are best managed with fluid 
restriction. If there is no improvement, low-dose loop diuretics and oral sodium chloride 
should be started. In these patients always consider the causes of SIAD and treat 
appropriately. Patients with hypovolemia should be given intravenous 0.9% sodium chloride 
or a balanced crystalloid solution at a rate of 0.5-1.0ml/kg/hour. Importantly, asymptomatic 
patients with mild hyponatraemia do not warrant aggressive treatment. Guidelines frequently 
reference the patient’s symptoms as the most important factor when considering treatment of 
hyponatraemia and treatment of mild hyponatraemia is only warranted when symptomatic. 
 
Rapid correction of serum sodium 
The treatments outlined above may result in a rapid correction of the serum sodium and 
serum osmolality. In rare cases, this may precipitate osmotic demyelination syndrome (ODS), 
which presents in patients with changes in mental status, rapid quadriplegia, and dysphagia 
[20]. There is an increased risk of developing ODS in patients with SIAD, significant burns 
and those who chronically abuse alcohol [21]. Whilst patients with a rapidly corrected 
chronic hyponatraemia are considerably more likely to develop ODS [22], there is a small 
number of patients described in the literature who have developed ODS following rapid 
correction of an acute hyponatraemia [23]. As such, we should bear in mind the risks of 
rapidly correcting serum sodium levels in all patients with hyponatraemia. 
 
To minimise the risk, guidelines recommend stopping the treatment of hyponatraemia if there 
is an increase in serum sodium >10mmol/L in the first 24 hours or >8mmol/L in each 
subsequent 24 hours. Close monitoring of the patient’s serum electrolytes is therefore 
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required, and as such aggressive management should only be sought in an appropriately 
close-monitored environment. In these circumstances, it is essential to seek expert advice on 
whether to begin an infusion of electrolyte free solutions (e.g. glucose solutions) whilst under 
strict fluid balance and urine output monitoring. 
 
Conclusion 
Hyponatraemia is a disorder which often presents non-specifically and has a considerable 
aetiological basis. Appropriate management of hyponatraemia takes account of the patient’s 
symptoms and the acute or chronic nature of onset. Appropriately educating doctors is 
important in improving clinical management which is often suboptimal in practice and 
essential in minimising the associated morbidity and mortality of the condition. The new 
guidelines summarised here will hopefully reduce the previous difficulty in teaching this 
important clinical topic to both medical students and doctors, which will ultimately improve 
the treatment of this common electrolyte disorder. 
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Main Messages 
• Hyponatraemia is a complex metabolic disorder which carries significant morbidity 
and mortality in hospital inpatients. 
• Hyponatraemia patients require thorough examination investigation to ascertain the 
cause which guides further management appropriately. 
• Management is not only guided by the absolute serum sodium level or underlying 
disorder, but guided mostly by the patient’s symptomatology. 
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